跳至主要内容
临床试验/NCT00510692
NCT00510692已完成2 期

A Two-Arm Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Patients Using the Purified Free Fatty Acid, Eicosapentaenoic Acid

S.L.A. Pharma AG1 个研究点 分布在 1 个国家目标入组 58 人开始时间: 2006年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
58
试验地点
1
主要终点
Absolute Change in the Number of Polyps Measured in a Focal Area of the Rectum.

研究概览

简要总结

This purpose of this study is to investigate whether the number and size of rectal polyps can be reduced in patients with Familial Adenomatous Polyposis (FAP) by using a highly-purified form of a naturally occurring substance, the omega-3 fatty acid, eicosapentaenoic acid (EPA).

详细描述

It has been found that people who consume a large amount of oily fish tend to have a lower risk of developing colon cancer. This is thought to be due to the omega-3 fatty acids present in oily fish, one of which is EPA. The effect of taking a 99% pure form of EPA (2g per day) compared with placebo capsules on the number and size of polyps in the rectum over a six month period will be investigated.

FAP is an inherited susceptibility to diffuse colorectal adenomas and colorectal carcinoma, occurring in close to 100% of unresected colons. It is caused by a germline mutation in the Adenomatous Polyposis Coli (APC) gene located in the long arm of chromosome 5. To prevent cancer development it is recommended that patients with FAP undergo colectomy with ileo-anal or ileo-rectal anastomosis (or colectomy and end-ileostomy) at a socially convenient time before polyp progression to malignancy and before the age of 25. Patients with the attenuated FAP phenotype, often associated with mutations at the 5' terminus (exon 4 and proximally), have fewer polyps and may often delay colectomy. Patients with an ileo-rectal anastomosis are still susceptible to polyp formation in the remaining rectal stump and require 6 monthly check-ups with a flexible sigmoidoscope with removal of any polyps that develop. Therefore, an effective chemopreventative agent with a favourable side-effect profile would be of benefit to FAP patients with ileo-rectal anastomosis (IRA) and recurrent rectal polyps in addition to young adults who prefer to delay colectomy. If such an agent were to be effective in FAP patients in the prevention of colonic polyps, it may also be of benefit to the larger population of patients with sporadic colorectal adenomatous polyps who are also at risk of colorectal cancer.

Colorectal polyps are thought, at least in part, to arise from an imbalance in the levels of cell proliferation and apoptosis (natural cell death) in the colonic mucosa. It has been suggested that omega-3 polyunsaturated fatty acids (PUFAs) in fish oil can manipulate the high levels of colonic-mucosal cell proliferation rates associated with colonic adenomas.

The rationale for this trial is based on the increasing evidence linking inflammatory processes and the development of a number of cancers, including bowel cancer. This has focused attention on the role of inflammatory mediators in the development of cancer. In particular, the family of eicosanoids (including 2-series prostaglandins, 4-series leukotrienes and thromboxanes) produced through conversion of the omega-6 PUFA, arachidonic acid, via cyclo-oxygenase-2 (COX-2) is believed to contribute to the physiological processes of inflammation and the development of tumours. Prostaglandin E2, a product of the conversion of arachidonic acid via the COX-2 pathway, has been implicated in tumourigenesis through:

  1. promotion of angiogenesis
  2. anti-apoptotic properties
  3. increasing expression of matrix metalloproteinases and hence the ability of a tumour cell to undergo metastasis
  4. altering the cytokine expression profile of cells.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects must have a known diagnosis of Familial Adenomatous Polyposis (FAP) and have had a previous colectomy with ileo-rectal anastomosis.
  • Males or females aged 18 and over
  • If the participant is female and of child bearing potential, she agrees to participate in this study by providing written informed consent, has been using adequate contraception (e.g. abstinence, condom, Intra-uterine device (IUD), birth control pill, diaphragm and spermicidal gel combination) since her last menses and will use adequate contraception during the study, is not lactating, and agrees to undergo a serum pregnancy test at baseline and month
  • Sexually active males must agree to use an accepted method of contraception.
  • Rectal polyp status: the subject has an endoscopically assessable rectal segment.
  • Subjects must show a willingness to abstain from regular use of non-steroidal anti-inflammatory medication for the duration of the study. A cardioprotective dose of aspirin (75mg) will be permitted.
  • Subjects must have provided written informed consent to participate.
  • Subjects must have assessable rectal polyps post baseline flexible sigmoidoscopy.
  • Subjects must have the following rectal polyp burden at the conclusion of the baseline endoscopy:
  • Rectum - 3 or more quantifiable polyps ≥2mm diameter
  • In the rectum quantifiable polyps are defined as being within a composite "cloverleaf" photograph that includes a tattoo.

排除标准

  • Subjects who are due to undergo an anticipated colectomy within 8 months of randomisation
  • History of invasive carcinoma in the past 5 years other than resected Dukes' A/B1 colon cancer or resected non-melanomatous skin cancer
  • Partial or complete colectomy within 12 months prior to enrolment.
  • History of pelvic radiation
  • Subjects who are allergic to fish
  • Subjects who have diabetes mellitus
  • Subjects who are pregnant or breast-feeding
  • Subjects taking aspirin or other non-steroidal anti-inflammatory drugs on a regular basis other than low dose (75 mg) cardioprotective dose.
  • Subjects who have aspirin-sensitive asthma
  • Subjects suffering from haemorrhagic disorders
  • Subjects who are taking warfarin or other anticoagulants
  • Subjects who have significant abnormalities on their screening blood tests
  • Subjects taking lipid lowering medication
  • Subjects with gastrointestinal malabsorptive disease
  • Subjects with known or prior coagulopathy
  • Subjects with uncontrolled hypercholesterolaemia
  • Subjects who are taking other fish-oil supplements (e.g. cod liver oil) who are unwilling to stop them for the duration of the study. Subjects previously taking fish oil must have a washout period of 1 month prior to study enrolment.
  • Subjects who are deemed mentally incompetent, or have a history of anorexia nervosa or bulimia
  • Subjects with a history of alcohol or drug abuse, including laxative abuse which would render the subject unreliable.
  • Subjects considered by their physician unlikely to be able to comply with the protocol.
  • Subjects who have taken part in an experimental drug study in the preceding 3 months.
  • Subjects who have a positive pregnancy test within 14 days prior to baseline visit.

研究组 & 干预措施

2g/day Eicosapentanoic Acid (EPA)

Experimental

Eicosapentanenoic Acid (EPA) as the free fatty acid 2 capsules twice daily for 6 months.

Endoscopy and biopsies taken as described under intervention.

干预措施: Eicosapentanoic Acid (EPA) (Drug)

2g/day Eicosapentanoic Acid (EPA)

Experimental

Eicosapentanenoic Acid (EPA) as the free fatty acid 2 capsules twice daily for 6 months.

Endoscopy and biopsies taken as described under intervention.

干预措施: Endoscopy (Procedure)

2g/day Eicosapentanoic Acid (EPA)

Experimental

Eicosapentanenoic Acid (EPA) as the free fatty acid 2 capsules twice daily for 6 months.

Endoscopy and biopsies taken as described under intervention.

干预措施: Biopsies taken (Procedure)

Placebo

Placebo Comparator

Medium chain triglycerides 2 capsules twice daily for six months. Endoscopy and biopsies taken as described under intervention.

干预措施: Endoscopy (Procedure)

Placebo

Placebo Comparator

Medium chain triglycerides 2 capsules twice daily for six months. Endoscopy and biopsies taken as described under intervention.

干预措施: Biopsies taken (Procedure)

Placebo

Placebo Comparator

Medium chain triglycerides 2 capsules twice daily for six months. Endoscopy and biopsies taken as described under intervention.

干预措施: Placebo (Drug)

结局指标

主要结局

Absolute Change in the Number of Polyps Measured in a Focal Area of the Rectum.

时间窗: 6 months compared to baseline.

Absolute change in the number of polyps measured in a defined focal area of the rectum.

次要结局

  • Change in Global Rectal Polyp Burden.(6 months compared to baseline.)
  • Relative EPA Concentration of Total Free Fatty Acids in the Rectal Mucosa.(6 months compared to baseline.)
  • Number of Subjects With Adverse Events.(6 months compared to baseline)
  • Percentage Change in the Number of Polyps Measured in the Defined Focal Area of the Rectum.(6 months compared to baseline.)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验